3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFujian Medical University
About this trial
Patients with locally advanced gastric adenocarcinoma (CT2-4a N-/+ M0) were selected as study subjects to investigate the safety, efficacy, and feasibility of ICG near-infrared imaging tracing in 3D plus ultra high resolution laparoscopic gastrectomy with lymph node dissection for gastric cancer.
Eligibility criteria
Qualifiers
Age from 18 to 75 years
Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy
cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition
No distant metastasis, no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations
Disqualifiers
Women during pregnancy or breast-feeding
Severe mental disorder
History of previous upper abdominal surgery (except for laparoscopic cholecystectomy)
History of previous gastric surgery (including ESD/EMR for gastric cancer)
Trial design
Treatments tested in this trial
- Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Treatment groups
702 Participants
are divided into 3 treatment groupsSponsors and collaborators
Fujian Medical University
Lead sponsor
Fujian Medical University Union Hospital
Sponsor institution
Source ClinicalTrials.gov